Designing CD8+ T cell vaccines: it's not rocket science (yet)
- PMID: 20447814
- PMCID: PMC2908899
- DOI: 10.1016/j.coi.2010.04.002
Designing CD8+ T cell vaccines: it's not rocket science (yet)
Abstract
CD8+ T cells play important roles in clearing viral infections and eradicating tumors. Designing vaccines that elicit effective CD8+ T cell responses requires a thorough knowledge of the pathways of antigen presentation in vivo. Here, I review recent progress in understanding the activation of naïve CD8+ T cells in vivo, with particular emphasis on cross-priming, the presentation of protein antigens acquired by dendritic cells from their environment. With the rapid advances in this area of research, the dawn of rational vaccine design is at hand.
Published by Elsevier Ltd.
References
-
- Teng MW, et al. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008;84:988–993. - PubMed
-
- Crowe SR, et al. Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge. J Immunol. 2005;174:696–701. - PubMed
-
- Yang OO, et al. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol. 2003;171:3718–3724. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
